New York, November 2nd / PRNewswire / -- DarioHealth Corp. (Nasdaq ticker: DRIO) ("Dario" or "the Company") announced today that it will release its financial results for the third quarter ending September 30, 2026, before the opening of U.S. stock markets on Thursday, November 12, 2026, and will hold a conference call and webcast at 8:30 a.m. Eastern Time.

The company's CEO Erez Raphael, Chief Operating Officer Lara Dodo, and Chief Financial Officers Chen Franco to Yehuda will preside over this teleconference.

Telephone Conference Details

• Date: Thursday, November 12, 2026, 8:30 a.m. Eastern Time, USA
• Dialing number: 1-800-717-1738 (within the United States) or 1-646-307-1865 (international)
• Call me ™: https :// emportal.ink /4623c5K
• Participants can use the above dial-in numbers to connect with the operator, or click on the link Call me ™ to access the event immediately. This link will become available 15 minutes before the scheduled start time.
• Live streaming link: https :// viavid.webcasts.com / starthere.jsp ? ei =1775359&tp_key=4596015d94

It is recommended that participants dial in about 10 minutes before the event starts. The recording of the teleconference will be available approximately 3 hours after the meeting ends and will be accessible until Thursday, November 26, 2026. To listen to the recording, please call 1-844-512-2921 (within the United States) or 1-412-317-6671 (international) and enter the playback password 1139413.

Regarding DarioHealth Corp.

DarioHealth Corp (Nasdaq ticker: DRIO) is a medical technology company driven by artificial intelligence (AI). It helps health plans, healthcare systems, and employers improve health outcomes while reducing healthcare costs. The company's comprehensive platform combines connected devices, personalized member interactions, AI-powered insights, and clinical care supported by healthcare providers to support individuals with needs such as diabetes, hypertension, weight management, musculoskeletal health, and behavioral health.

Leveraging over 1.3 billion unique longitudinal medical data points collected over more than a decade, the AI platform of Dario achieves personalized care at the individual member level by analyzing biometric, clinical, and behavioral data, thereby providing more timely and effective interventions. By integrating interaction, clinical intelligence, and nursing services into a single platform, Dario helps customers manage a variety of chronic diseases through a comprehensive solution.

Warning Regarding Forward-Looking Statements

This press release, as well as the statements made by DarioHealth Corp and its partners herein, contain or may contain forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Statements that are not historical facts may be considered forward-looking statements. For example, the company uses forward-looking statements when discussing the expected date of its earnings releases in this press release. Without limiting the foregoing generalities, words such as “plans,” “expects,” “potential,” “seeks,” “may,” “will,” “expects,” “believes,” “anticipates,” “intends,” “can,” “estimates,” or “continues” are intended to identify forward-looking statements. Readers are reminded that certain important factors may affect the company’s actual results and may cause significant differences between those actual results and any forward-looking statements contained in this press release. Factors that may affect the company’s performance include, but are not limited to, regulatory approvals, product demand, market acceptance, the impact of competitive products and prices, product development, commercialization or technical difficulties, the success or failure of negotiations and transactions, legal, social, and economic risks, and risks related to the adequacy of existing cash resources. Other factors that may cause or contribute to differences between the company’s actual results and forward-looking statements include, but are not limited to, the risks discussed in the company’s filings with the U.S. Securities and Exchange Commission. Readers are also reminded that actual results (including, but not limited to, the timing and outcomes of Dario™’s business and regulatory plans as described in this document) may differ significantly from those stated in the forward-looking statements. Except as required by applicable law, the company has no obligation to publicly update any forward-looking statements due to new information, future events, or other reasons.

DarioHealth Company Contact Information

Zoe Harrison

DarioHealth Investor Relations Contact Information

Michael Lipari